Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study

Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer

Pieter van Hagen, Maarten C.C.M. Hulshof, J. Jan B. van Lanschot et al. · New England Journal of Medicine · 2012 · 5.5K citations · Full text

Medicine, Oncology, Surgery +14

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study

Jong‐Mu Sun, Lin Shen, Manish A. Shah et al. · The Lancet · 2021 · 1.6K citations · Full text

Medicine, Oncology, Pharmacology +14

A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907)

Nobutoshi Ando, Hoichi Kato, Hiroyasu Igaki et al. · Annals of Surgical Oncology · 2011 · 1.4K citations

Medicine, Oncology, Surgery +10

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

New England Journal of Medicine · 2022 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Validity and Reliability of the US National Cancer Institute’s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)

Amylou C. Dueck, Tito R. Mendoza, Sandra A. Mitchell et al. · JAMA Oncology · 2015 · 1K citations · Full text

Pharmacy, Oncology, Outcomes Research +13